We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

116 hedge funds and large institutions have $39.6M invested in Sanofi Contingent Value Rights in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

15% more capital invested

Capital invested by funds: $34.4M → $39.6M (+$5.12M)

6% more funds holding

Funds holding: 109116 (+7)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 16

Holders
116
Holders Change
+7
Holders Change %
+6.42%
% of All Funds
3.09%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
16
Reduced
16
Closed
4
Calls
Puts
Net Calls
Net Calls Change

GCVRZ Hedge Fund Activity: Q3 2016 in Review

116 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2016, worth a combined $39.6M — up 15% from $34.4M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new GCVRZ positions and 4 closed out — a net gain of 9 holders — while 16 added to existing stakes and 16 trimmed.

The largest buyer was Brigade Capital Management, opening a new position worth an estimated $3.09M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $1.15M sold.

  • 116 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2016, up from 109 in Q2 2016.
  • Funds reported $39.6M of Sanofi Contingent Value Rights stock for Q3 2016, up 15% quarter-over-quarter.
  • 13 funds opened new Sanofi Contingent Value Rights positions in Q3 2016 and 4 closed out, a net change of +9 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q3 2016 was Brigade Capital Management, an estimated $3.09M added.
  • The largest Sanofi Contingent Value Rights seller in Q3 2016 was Oxford Asset Management, an estimated $1.15M sold.

Based on aggregated 13F filings for Q3 2016.